Announcing a New Era in Alzheimer's

Announcing a New Era in Alzheimer's PR Newswire MONTE CARLO, Monaco, October 30, 2012 MONTE CARLO, Monaco, October 30, 2012 /PRNewswire/ -- The time for Tau is now as Phase 3 clinical trials get under way with a second-generation Tau Aggregation Inhibitor (TAI) aimed at halting the progression of Alzheimer's TauRx Therapeutics Ltd announced today the initiation of two global Phase 3 clinical trials in mild to moderate Alzheimer's disease. These landmark studies could provide the first definitive data on a Tau-based approach to disease-modifying and preventative treatment of Alzheimer's for at least the next 5-7 years, said Professor Claude Wischik, Chairman of TauRx and Professor of Old Age Psychiatry at the University of Aberdeen, in a press conference at the 5th Clinical Trials Conference on Alzheimer's Disease (CTAD) in Monte Carlo, Monaco today. The studies culminate three decades of research by Professor Wischik and colleagues, including the original discovery of the Tau protein as the main constituent of the Tangle pathology of Alzheimer's disease ['Tau tangles'], the development of the first Tau Aggregation Inhibitor (TAI), and results from an earlier Phase 2 clinical trial involving more [1]than 300 patients that showed a 90% reduction in the rate of disease progression over two years. "These Phase 3 studies are bringing us closer to finding an effective treatment that can actually arrest the progression of the disease," said Professor Wischik.